This round is no longer accepting investments, but hundreds just like it are live now.

Log In


AI-Driven Disease Screening Software

iHealthScreen is an AI-driven HIPAA-compliant med-tech company with incoming product traction in several international markets, using AI to Scalably Screen for Retinal Diseases, Stroke, and Heart Disease. Early diagnosis and intervention can prevent blindness, save countless lives & eliminate massive amounts of downstream spending. iHealthScreen is in the pre-revenue stage of development. Some of the information on the campaign page was obtained via the Company's relationship with iHealthScreen Ltd. (Abu Dhabi), which is an LLC, also owned by Alauddin Bhuiyan, PhD, CEO. There is a software license agreement between the two entities, allowing iHealthScreen Ltd. to use the Company's IP and software portfolios.

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

$189,865.28 Raised


iHealthScreen is entering what we believe is almost an entirely untapped, multi-billion-dollar global market ($9.5B in USA only). With regulatory approvals already achieved in key markets, along with the established reimbursement code for screening in place approved for European and most of the Asian markets, we believe iHealthScreen is poised to successfully commercialize its products. iHealthScreen’s first product, iPredictTM, is market ready, with one patent received and multiple patents pending, and we’re anticipating AMD & DR FDA 510(K) clearances by mid-2023. Already having a large hospital chain as a customer and a licensing agreement is in place with one of the top camera companies in the world, we believe demonstrates traction with key strategic partners.

To the best of our knowledge, iHealthScreen is the first company in the world to receive CE certification for three blinding eye disease screening: AMD, DR, and glaucoma. In addition, iHealthScreen has developed and validated prediction models for strokes, heart attacks, and cardiovascular diseases. We have seen stroke and heart attack prediction accuracy is almost 10% higher than the existing clinically used prediction models (Framingham and CHADS scores), with additional tools in development phase for Alzheimer’s and dementia prediction.

iHealthScreen has been awarded $2.7M in NIH funding, raised $750K as seed funding and we are working on securing additional research grants. We have received one US patent (the first patent in Late AMD prediction), one patent is pending and four provisional patent applications are submitted. The company’s work on retinal disease screening is featured in the world's largest ophthalmology conference ARVO 2018, and the American Academy of Ophthalmology (AAO) 2020. The stroke prediction results were presented at the Society for Brain Mapping Conference 2021.

the pitch

iHealthScreen is bringing low-cost, AI-driven screening software to primary care offices around the world to provide routine access to disease prevention that would otherwise be limited to specialty care. We’ve been awarded $2.7M in NIH funding and are in the process of receiving an additional $6.5M from private investors and research grants, with one patent received and multiple patents pending. Our first product, iPredictTM, has the capability to screen for late age-related macular degeneration (AMD), diabetic retinopathy (DR), glaucoma, stroke, heart attack, and cardiovascular heart disease, and we have additional tools in development for Alzheimer’s, dementia and hypertensive retinopathy. By facilitating large-scale, low-cost screening, our software presents wide-reaching impact and huge potential for growth.

A New Leader in AI-Driven Disease Prevention

iHealthScreen’s integrated, retinal imaging-based system makes us one of the first companies in the world to receive CE certification, Australian and UAE Health approvals for AMD, DR, and glaucoma screening. We’re already gaining international traction with contracts in the US, EU, Bangladesh, and UAE, and have been collaborating with Global Victoria, Australia. 

iHealthScreen is poised to be a leader in this new area of AI-driven disease prevention, providing critical value to individuals, medical providers, and insurance providers and presenting enormous growth potential to investors.

The Problem & Our Solution

Preventative Screening Should Be Easy, Fast, and Accessible

Our current medical systems—the US serving as the most glaring example—cost patients and providers billions of dollars while often failing to improve overall health outcomes, especially at a preventive level. Primary care doctors lack the resources to provide more than the most basic screenings, and most people don’t have the time or resources to schedule regular screenings with specialists. This results in serious health consequences and large financial burdens, for patients, providers, and insurers alike.

*The features shown in the graphic above reflect features for a product that has not received FDA 510K clearance. The product is not currently available to the general public for sale.

iHealthScreen’s software makes preventative screening for ailments such as eye disease, diabetes, cardiovascular disease, heart attack and stroke easy, fast, and accessible. By lowering costs and expanding access, we’re looking to make screening for a larger set of diseases a seamless, built-in component of your annual check-up, especially for aging patients. In addition to our screening software, we’re aiming to add a built-in telemedicine capability to ensure patients can receive immediate care when and wherever needed. 

The Market & Our Traction

A Newly Opened, Multi-Billion-Dollar Global Market

The current market size for screening diabetic retinopathy (DR) and age-related macular degeneration (AMD) is projected at $9.5B, in USA only, with the global diabetic population estimated to reach 578 million by 2030, it should be 3x. 


The introduction of CPT code 92229 in 2021 has opened up the screening market, allowing coverage for retinal imaging for the detection or monitoring of disease. As of now, this massive market is almost entirely untapped, we believe less than 1% of the market is taken by companies that have received FDA 510(K) clearance—providing ideal timing for iHealthScreen’s FDA clearance and market entry. FDA 510K application on AMD screening is already submitted. The 510K application for DR screening is in the final stage of submission. The company expects to obtain these two FDA 510K clearances by the middle of this year and achieve an advantageous position to become commercially successful.

iHealthScreen’s first product, iPredictTM, is market ready, with one patent received and multiple patents pending, and we’re anticipating FDA 510(K) clearance by mid-2023. We’re now one of the first companies in the world to receive CE certification for AMD, DR, and glaucoma screening, and have received approval from Health Australia and Health UAE.

We’ve secured a total of $2.7M in NIH funding, which is being applied towards a three-year prospective trial on late AMD prediction, along with a NIH SBIR Phase II grant for stroke prediction. We’ve signed a licensing agreement with iCare in Finland, an agreement with the Bangladesh Diabetes Society to screen 5.5 million registered diabetics in Bangladesh, as well as another with Burjeel Hospital UAE for DR screenings which has 40 clinics in the Gulf region with billions of dollars in revenue (source).

Why Invest

Invest in the Future of Preventive Healthcare

Streamlined, hassle-free disease screening should be a part of every patient’s annual routine. We’re looking at huge potential for growth, scale, and global impact—and we believe now is the perfect time to join us. 

Invest in iHealthScreen & help us on our mission to provide low-cost, advanced screening software in primary care offices across the world - help prevent blindness, deaths and disability. 

*The features shown in the graphic above reflect features for a product that has not received FDA 510K clearance. The product is not currently available to the general public for sale.


132-02 89th Av, Suite 214
Richmond Hill, NY 11418

iHealthScreen is an AI-driven HIPAA-compliant med-tech company with incoming product traction in several international markets, using AI to Scalably Screen for Retinal Diseases, Stroke, and Heart Disease. Early diagnosis and intervention can prevent blindness, save countless lives & eliminate massive amounts of downstream spending. iHealthScreen is in the pre-revenue stage of development. Some of the information on the campaign page was obtained via the Company's relationship with iHealthScreen Ltd. (Abu Dhabi), which is an LLC, also owned by Alauddin Bhuiyan, PhD, CEO. There is a software license agreement between the two entities, allowing iHealthScreen Ltd. to use the Company's IP and software portfolios.


Alauddin Bhuiyan, PhD
Alauddin Bhuiyan, PhD
Founder and CEO

Dr. Alauddin Bhuiyan is an inventor, innovator, and computer scientist with deep life science and medical technology expertise covering the spectrum of life science and med-tech. He is the founder and CEO of iHealthScreen Inc. and has been working in the retinal imaging and image-based disease screening area for more than 15 years. He has been with the company as full-time since January 2017. Before that, he was a faculty member in the department of Computer Science at New York University. He was a visiting scholar at Harvard Medical School and was the recipient of the prestigious Endeavor Australia Award 2014 and was recognized as a distinguished Australian. He has been holding an Adjunct Associate Professor position at New York Eye and Ear Infirmary, Icahn School of Medicine at Mount Sinai since July 01, 2019.

Dr. Bhuiyan led the developing iPredictTM a HIPAA-compliant AI-powered software tool, which is based on Electronic Health Record (EHR) and telemedicine platform to screen and predict individuals at risk of diabetic retinopathy (DR), Age-related Macular Degeneration (AMD), Glaucoma, heart disease and stroke (

The AMD, DR, and glaucoma screening tools are already CE certified, Abu Dhabi Health and Australian Health approved.

Dr. Bhuiyan is the inventor of the first image-based prediction tool for age-related macular degeneration (AMD). A full US patent is awarded to iHealthScreen Inc. This work was selected as featured work at ARVO 2018, the largest ophthalmology conference in the world. Also, the American Academy of Ophthalmology selected his work for the panel discussion in 2020. His interview can be viewed at

Dr. Bhuiyan has received almost $5M Federal and state grants through various stages of his career. He secured more than $2.7M grants (another $2.2M is under consideration) for his company through NIH SBIR grants a Principal Investigator. 

Dr. Bhuiyan received his Ph.D. from the University of Melbourne, Australia, one of the top universities in the world (No. 1 in Australia). He joined at the Centre for Eye Research Australia (CERA) as a post-doctoral research fellow in 2009. Following this - in 2011, he joined at Commonwealth Scientific and Industrial Research Organization (CSIRO, which is the inventor of WiFi Technology) as a research scientist.

While at CSIRO, Dr. Bhuiyan developed a software tool that can predict an individual’s genetic association with Alzheimer’s disease, a patented technology currently being used by Neurovision.

As an innovator and technology developer, he has been at the core of medical products and technologies which have transformed the ophthalmic field and are impacting medical care for hundreds of thousands of patients every year.

Dr. Bhuiyan is a holder of multiple issued and pending patents. He has multiple high-impact publications in the field and published more than a hundred research articles, which have been cited by more than a thousand peer-reviewed publications. He is a senior member of IEEE Computer Society and IEEE Engineering in Medicine and Biology. He served on the technical committee for many IEEE conferences and journals.

Travis Millman, MAPP

Travis Millman, MAPP

Strategic Advisor

As a startup veteran with a penchant for developing and launching breakthrough products, Travis has played many roles during the course of his career. He was as Chief Operating Officer at Neuvotion, an early-stage medical device startup working on a next generation approach to neuromuscular electrical stimulation. He has been working on everything from the headiest of strategy development and refinement to the block and tackling aspects of building and growing a company.

Travis works 1 hour per week on iHealthscreen

Ms. Kathleen Adams, MBA

Ms. Kathleen Adams, MBA

Chief Marketing Officer

The clinical innovations patients need require integrating the benefits of several domains: biotech, pharma, diagnostics, genomics, and digital health. Having worked in all of these areas gives me the breadth and range to excel at cross-functional leadership, and the passion to keep the patient in mind. 

From market assessment to launch and implementation, I focus on new approaches to healthcare, particularly for life-threatening illnesses. Discoveries and inventions are essential, but not sufficient, to improving healthcare: closing the gap between new capabilities and the realities of care delivery is the only route to meaningful change for the better.

I nurture innovations -- new disease insights, new therapeutic or diagnostic technologies -- by working backward from the patient or provider, while others on the team work forward from the science. I've worked in marketing, business development, technology evaluation and patient advocacy roles at diagnostics companies, clinical laboratories and pharma and biotechnology companies, conducting pre-market evaluations, producing and executing development plans, and leading product launch campaigns for pharmaceutical and diagnostic products, as well as a suite of targeted diagnostic services. I've led commercial teams and strategic initiatives, served on a corporate board and a senior management team, and influenced at the senior executive level to bring about institutional change and enable new approaches to team-driven development.

My experience in establishing coalitions across the for-profit/not-for-profit divide, as well as my interdisciplinary team leadership efforts, are growing in relevance during this period of rapid industry restructuring and technology advancements. The explosion of health information and new technologies occurring simultaneously with the shift of decision-making responsibility to patients/consumers is driving change in a challenging way. The potential for more relevant, focused and personalized care is evident; the potential risks to patients without a deep understanding of science and medicine are daunting. Attention to health literacy, patient-centered research and implementation science are essential to help us optimize the benefits of new approaches. 

Ms. Kathleen Adams works 8-16 hours per week on iHealthscreen

Thomas Gerson, MBA

Thomas Gerson, MBA


Through his decades of financial and business operations acumen in the life sciences covering such key functions as capital formation, strategic partnering, business development, and financial planning & analysis, Tom has the proven ability to identify and align an emerging growth company’s underlying capabilities with its most attractive commercialization opportunities thereby maximizing potential value creation and financial returns.

As a CFO, he raised more than $100M for his previous companies.


Aug 2, 2023
$10k - $1.23M
Common Stock
Common Stock

Maximum Number of Shares Offered subject to adjustment for bonus shares

Most Recent Fiscal Year-End

Prior Fiscal Year-End

Total Assets



Cash & Cash Equivalents



Accounts Receivable



Short-Term Debt



Long-Term Debt



Revenue & Sales



Costs of Goods Sold



Taxes Paid



Net Income



*Maximum number of shares offered subject to adjustment for bonus shares. See Bonus info below.

Voting Rights of Securities Sold in this Offering

Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.

Investment Incentives & Bonuses*


Friends and Family Early Birds

Invest within the first 48 hours and receive 15% bonus shares.

Super Early Bird Bonus

Invest within the first week and receive 10% bonus shares.

Early Bird Bonus

Invest within the first two weeks and receive 5% bonus shares.


$1,000+ | Tier 1

Invest $1,000 and receive access 2% Bonus Shares.

$2,500+ | Tier 2

Invest $2,500 and receive access 3% Bonus Shares.

$5,000+ | Tier 3

Invest $5,000 and receive access 5% Bonus Shares.

$10,000+ | Tier 4

Invest $10,000 and receive access 10% Bonus Shares + zoom call with iHealthScreen’s founder.

*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

iHealthScreen, Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $2.63 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $263. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus in addition to the aforementioned bonus.

Irregular Use of Proceeds

The Company will not incur any irregular use of proceeds.


Article Image

iHealthScreen’s Artificial Intelligence (AI) Based Tool Can Accurately Diagnose Age-Related Macular Degeneration (AMD) and

Article Image
Yahoo Finance

HealthScreen Completed Prospective Trial of AI-Based Tool for Age-Related Macular Degeneration (AMD) Screening and Submitting the Results to FDA for 510K Clearance

Article Image
Diagnostic and Interventional Cardiology

iHealthScreen Inc. Introduces An Automated Stroke Prediction Model, based on AI and Color Fundus Imaging

Article Image
Business Wire

iHealthScreen Inc. is Awarded US Patent on Late Age-related Macular Degeneration (AMD) Prediction Model, which is based on AI and Color Fundus Imaging


Owners bonus
Stack Owner's Bonus & Rewards!

Members get an extra 10% shares in addition to rewards below!


Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into iHealthScreen.



Karl Stine

6 months ago

How does this system compare to other products currently available such as Eyenuk that can bill under CPT 92229?




Cancel anytime before 48 hours before a rolling close or the offering end date.



We want you to succeed and get the most out of your money by offering rewards and memberships!


Your info is your info. We take pride in keeping it that way!


Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.


Get To Know Us

Our Team



Important Message

Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRASIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.

Investment opportunities posted and accessible through the site are of three types:

1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.
By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.

Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

California Investors Only – Do Not Sell My Personal Information

(800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to

StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.

StartEngine Marketplace

The availability of company information does not indicate that the company has endorsed, supports, or otherwise participates with StartEngine.

None of the information displayed on or downloadable from (the 'Website') represents a recommendation, offer, or solicitation of an offer to buy or sell any security. It also does not constitute an offer to provide investment advice or service. StartEngine does not (1) make any recommendations or otherwise advise on the merits or advisability of a particular investment or transaction, or (2) assist in the determination of fair value of any security or investment, or (3) provide legal, tax, or transactional advisory services.

All investment opportunities are based on indicated interest from sellers and will need to be confirmed.

Investing in private company securities is not suitable for all investors. An investment in private company securities is highly speculative and involves a high degree of risk. It should only be considered a long-term investment. You must be prepared to withstand a total loss of your investment. Private company securities are also highly illiquid, and there is no guarantee that a market will develop for such securities. Each investment also carries its own specific risks, and you should complete your own independent due diligence regarding the investment. This includes obtaining additional information about the company, opinions, financial projections, and legal or other investment advice. Accordingly, investing in private company securities is appropriate only for those investors who can tolerate a high degree of risk and do not require a liquid investment.

StartEngine Marketplace (“SE Marketplace”) is a website operated by StartEngine Primary, LLC (“SE Primary”), a broker-dealer that is registered with the SEC and a member of FINRA and the SIPC. StartEngine Bulletin Board ("SE BB") is a bulletin board platform that advertises interest in shares of private companies that previously executed Reg CF or Reg A offerings. SE BB enables shareholders to communicate interest in potential sales of shares in private companies and investors to discover, review, and potentially invest in private companies. As a bulletin board platform, SE BB provides a venue for investors to access information about private company offerings and connect with potential sellers. SE BB is distinct and separate from StartEngine Secondary (“SE Secondary”), which is an SEC-registered Alternative Trading System (ATS) operated by SE Primary. SE Secondary facilitates the trading of securities by matching orders between buyers and sellers and facilitating executions of trades on the platform. While a security may be displayed on the bulletin board, these securities will be subject to certain restrictions which may prevent the ability to buy and sell these securities in a timely manner, if at all. Even if a security is qualified to be displayed on the bulletin board, there is no guarantee an active trading market for the securities will ever develop, or if developed, be maintained. You should assume that you may not be able to liquidate your investment for some time or be able to pledge these shares as collateral.